化學發光企業跨界保健品，做成京東銷量第一！

醫業觀察

02/12

有觀點，有態度這是醫業觀察的第2691-3期文章作者：凱莉醫業觀察編輯近日，醫業觀察編輯凱莉刷朋友圈，被一則喜報吸引——來自南京仁邁生物金總朋友圈的官宣，該公司旗下的保健品做到了京東NMN類目銷量第一！金總該朋友圈內容如下：願望實現了銷冠認證RealMind 雙向臻護 NMN24000 登頂京東 NMN 類目銷量第一上線即爆款，實力領跑抗衰新賽道！很多IVD同行都知道，仁邁生物的主業是做化學發光的...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2610807920"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610807920\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610807920?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-02-12 22:11","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2610807920","market":"hk","top_or_hot":-1,"title":"化學發光企業跨界保健品，做成京東銷量第一！","media":"醫業觀察","content":"<div>\n<p>有觀點，有態度這是醫業觀察的第2691-3期文章作者：凱莉醫業觀察編輯近日，醫業觀察編輯凱莉刷朋友圈，被一則喜報吸引——來自南京仁邁生物金總朋友圈的官宣，該公司旗下的保健品做到了京東NMN類目銷量第一！金總該朋友圈內容如下：願望實現了銷冠認證RealMind 雙向臻護 NMN24000 登頂京東 NMN 類目銷量第一上線即爆款，實力領跑抗衰新賽道！很多IVD同行都知道，仁邁生物的主業是做化學發光的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021222532797a5faa9&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>化學發光企業跨界保健品，做成京東銷量第一！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n化學發光企業跨界保健品，做成京東銷量第一！\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">醫業觀察</strong><span class=\"h-time small\">2026-02-12 22:11</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>有觀點，有態度這是醫業觀察的第2691-3期文章作者：凱莉醫業觀察編輯近日，醫業觀察編輯凱莉刷朋友圈，被一則喜報吸引——來自南京仁邁生物金總朋友圈的官宣，該公司旗下的保健品做到了京東NMN類目銷量第一！金總該朋友圈內容如下：願望實現了銷冠認證RealMind 雙向臻護 NMN24000 登頂京東 NMN 類目銷量第一上線即爆款，實力領跑抗衰新賽道！很多IVD同行都知道，仁邁生物的主業是做化學發光的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021222532797a5faa9&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021222532797a5faa9&s=b\">醫業觀察</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0417516902.SGD","symbol_name":"Allianz China Equity Cl AT Acc SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021222532797a5faa9&s=b","article_id":"2610807920","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021222532797a5faa9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610807920","pubTimestamp":1770905495,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"有觀點，有態度這是醫業觀察的第2691-3期文章作者：凱莉醫業觀察編輯近日，醫業觀察編輯凱莉刷朋友圈，被一則喜報吸引——來自南京仁邁生物金總朋友圈的官宣，該公司旗下的保健品做到了京東NMN類目銷量第一！誰能想到，這家IVD企業，居然跨界扎進了保健品賽道，更厲害的是，剛出手就拿到了京東NMN類目銷量第一！凱莉認為，IVD企業做化妝品，最大的底氣莫過於「降維打擊」的先天優勢。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"89618":"京东集团-SWR","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU1044874839.SGD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"AGH\" (SGDHDG) ACC","LU0164865239.USD":"HSBC GIF CHINESE EQUITY \"AC\" (USD) ACC","LU0084288322.USD":"Natixis Asia Equity RD USD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","BK1591":"就地过年概念","LU1282651121.HKD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"AMG\" (HKD) INC","LU0228367735.SGD":"Eastspring Investments - Asian Equity Fund AS SGD","LU0345775950.USD":"NINETY ONE GSF ASIAN EQUITY \"A\" (USD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0164880469.USD":"HSBC GIF HONG KONG EQUITY \"AC\" ACC","LU0588545904.SGD":"Eastspring Investments - Asian Equity Income ASDM SGD","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0588545730.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY INCOME \"ADM\" (USD) INC","09618":"京东集团-SW","IE00B3M56506.USD":"NEUBERGER BERMAN EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","06618":"京东健康","LU0588545490.SGD":"Eastspring Investments - Asian Equity Income AS SGD","BK1610":"ETF&股票定投概念","LU0531971595.HKD":"HSBC GIF CHINESE EQUITY \"AD\" (HKD) INC","LU0052750758.USD":"富兰克林中国基金A Acc","LU0791591158.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"I\" (USD) ACC","LU0384037296.USD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AT\" (USD) ACC","LU0488056044.USD":"Allianz Asian Multi Income Plus Cl AM DIS USD","BK1575":"同股不同权","IE00BGV7N243.SGD":"FSSA Global Emerging Markets Focus I Acc SGD","LU0315178854.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY INCOME \"A\" ACC","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0345776255.USD":"NINETY ONE GSF ASIAN EQUITY \"A\" (USD) INC","LU1224444064.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"AM\" (USDHDG) INC","LU0048580855.USD":"富达大中华区A","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0293314216.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"A\" (USD) ACC","IE00B29SXG58.USD":"FSSA CHINA FOCUS \"I\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","LU1282651048.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"AMG\" (USD) INC","LU0348805143.USD":"ALLIANZ ENHANCED ALL CHINA EQUITY \"A\" (USD) INC","LU1720050803.USD":"安联全方位中国股票基金","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0149721374.USD":"HSBC GIF HONG KONG EQUITY \"AD\" INC","LU0231483743.USD":"abrdn SICAV I - ALL CHINA SUSTAINABLE EQUITY \"A\" (USD) ACC","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","LU0791590937.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"A\" (USD)","LU1282649810.SGD":"Allianz Asian Multi Income Plus Cl AMg DIS H2-SGD","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","LU0163747925.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY A ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","BK1502":"双十一","LU0499858602.USD":"NINETY ONE GSF ASIA PACIFIC EQUITY OPPORTUNITIES \"A\" (USD) ACC","IE0032431581.USD":"PINEBRIDGE GREATER CHINA EQUITY \"A\" (USD) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0868486357.SGD":"JPMorgan Funds - Emerging Markets Opportunities A (acc) SGD-H","LU1366334651.USD":"ALLSPRING EMERGING MARKETS EQUITY INCOME \"I\" (USD) INC","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","SG9999002828.SGD":"Eastspring Investments Unit Trusts - Dragon Peacock A SGD","LU0594300419.USD":"富达中国消费基金A","LU1770036033.HKD":"NINETY ONE GSF ASIAN EQUITY \"A\" (HKD) ACC","BK1142":"互联网与直销零售","LU0650527681.SGD":"Fidelity China Consumer A-SGD","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","LU2257852520.SGD":"JPMorgan Funds - Asia Growth A (acc) SGD","BK1588":"回港中概股","LU0320764755.SGD":"FTIF - Templeton Asian Growth A Acc SGD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0128522157.USD":"TEMPLETON ASIAN GROWTH \"A\" ACC","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0871576103.HKD":"HSBC GIF CHINESE EQUITY \"AC\" (HKD) ACC","BK1615":"港股-互联网","LU1282649067.USD":"ALLIANZ ASIAN MULTI INCOME PLUS \"AMG\" (USD) INC A","LU0431992006.USD":"摩根大通新兴市场机会A（acc）","LU0865486749.SGD":"Eastspring Investments - Asian Equity Income AS SGD-H","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0469268626.HKD":"AB FCP I-ASIA EX JAPAN EQUITY PTF(AD","LU0499858438.USD":"NINETY ONE GSF ASIA PACIFIC EQUITY OPPORTUNITIES \"A\" (USD) INC","LU1044875133.USD":"天利亚洲反向股票 AU Acc","BK1619":"稳定币概念","SG9999001226.SGD":"UNITED SUSTAINABLE ASIA TOP 50 \"A\" (SGD) ACC","LU0259732245.USD":"EASTSPRING INVESTMENTS DRAGON PEACOCK A","LU0029875118.USD":"TEMPLETON ASIAN GROWTH \"A\" INC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","LU0828237510.HKD":"SCHRODER ISF BIC (BRAZ IN CH)\"A\" (HKD) ACC","LU0672654166.SGD":"FTIF - Templeton Asian Growth A (acc) SGD-H1","BK1249":"综合零售","LU0228659784.USD":"施罗德金砖四国基金","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","LU0370786039.SGD":"Fidelity Greater China A-SGD","LU0051755006.USD":"摩根大通中国A (dist)","LU0543330483.HKD":"TEMPLETON ASIAN GROWTH \"A\" (HKD) ACC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU1044876610.USD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"ZU\" (USD) ACC","LU1481107354.HKD":"HSBC GIF HONG KONG EQUITY \"AD\" (HKD) INC","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU1366334578.USD":"ALLSPRING EMERGING MARKETS EQUITY INCOME \"A\" (USD) INC","LU1642822792.SGD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"A\" (SGD) ACC"},"translate_title":"Cross-border health care products of chemiluminescence enterprises have become the number one seller in JD.com!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"89618":0.6,"06618":1.87,"09618":0.9},"content_text":"有觀點，有態度這是醫業觀察的第2691-3期文章作者：凱莉醫業觀察編輯近日，醫業觀察編輯凱莉刷朋友圈，被一則喜報吸引——來自南京仁邁生物金總朋友圈的官宣，該公司旗下的保健品做到了京東NMN類目銷量第一！金總該朋友圈內容如下：願望實現了銷冠認證RealMind 雙向臻護 NMN24000 登頂京東 NMN 類目銷量第一上線即爆款，實力領跑抗衰新賽道！很多IVD同行都知道，仁邁生物的主業是做化學發光的，深耕體外診斷領域10年，踏踏實實做試劑、做設備，在行業裏也算有口皆碑。據仁邁生物公司官網信息，仁邁生物專注於「一老一小」特色檢測試劑項目以及末梢血全血全自動檢測平台的研發、生產和銷售。檢測試劑產品包括兒童營養及生長發育、危急重症、腦損傷、阿爾茨海默症、血栓、骨質疏鬆檢測等臨床特色項目，共獲得NMPA產品註冊證70+項，CE認證100+項。累計裝機數量800+台，覆蓋全國25個省，客户中三甲醫院佔比約50% 。仁邁生物目前是羅氏診斷和金賽藥業的合作伙伴，已完成C輪融資，投資方包括紅杉資本等知名機構。誰能想到，這家IVD企業，居然跨界扎進了保健品賽道，更厲害的是，剛出手就拿到了京東NMN類目銷量第一！編輯凱莉特意去京東搜了一下，果然，這款來自仁邁生物的NMN產品，居於類目銷量榜首，評論區很多消費者的好評，「性價比拉滿」，「不愧是醫療背景企業做的，很有效果」。2026年1月21日，醫業觀察 編輯凱莉注意到 不菲BuFei 公眾號發布文章，推出針對油性肌膚顯性問題的全周期抗衰護膚品套裝。而這家企業正是IVD行業龍頭企業邁克生物參與投資的企業。參考邁克投資的企業，出化妝品了！IVD企業跨界美妝在業內早已不算是「新聞」。熱景生物旗下「蔻生元」「EXOMICS茵頌」雙品牌齊發力，依託植物外泌體技術推出醫研級抗衰產品，天貓旗艦店已形成完整產品矩陣，甚至聯合行業協會發布技術白皮書樹立標準；熱景生物：新獲23項國內外醫療器械及化妝品資格認證博科生物也高調佈局美妝原料與護膚品研發，憑藉生物實驗室優勢探索成分創新。IVD企業集體跨界美妝，絕非一時興起，而是產業邏輯與市場需求共同作用的必然結果。IVD行業這幾年面臨集採的壓力，企業為了生存發展，跨界經營無可厚非。凱莉認為，IVD企業做化妝品，最大的底氣莫過於「降維打擊」的先天優勢。從監管適配性、技術複用性和市場需求匹配的角度，都非常契合。其一，監管適配性強醫療器械與化妝品均由國家藥監局監管，儘管二者在上市前審批、質量體系要求上存在差異——如醫療器械強制符合QSR體系，化妝品以備案制為主，但IVD企業長期浸潤在嚴格的合規體系中，對原料把控、生產規範、標籤合規的理解遠超普通美妝品牌，這種「醫療級嚴謹」自帶安心屬性，恰好擊中消費者對護膚品安全性的核心訴求。其二，技術複用性高IVD行業對人體生理機能、生物成分的研究深度，是普通美妝企業難以企及的。熱景生物將納諾革裝載技術應用於抗衰產品，邁克依託生物檢測技術對肌膚問題的精準洞察，本質上都是將IVD的核心技術平移至美妝領域。這種技術賦能下的產品，能構建差異化競爭壁壘。其三，市場需求精準匹配「理性消費」當下消費者追求「健康與美」的雙重需求，醫療背景加持的保健品、護膚品，天然契合這種消費趨勢。有醫療技術撐腰、有合規體系把關，才能真正讓消費者買得放心、用得安心，這或許就是IVD企業跨界最大的底氣。為仁邁生物讚好！作者：凱莉","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}